Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia

Neuroendocrinology Letters

Volumn 31, Issue 1, 2010, Pages 117-121

  Emanuele, Enzo ^a   Colombo, Roberto ^a   Martinelli, Valentina ^a   Brondino, Natascia ^a   Marini, Mara ^a   Boso, Marianna ^a   Barale, Francesco ^a   Politi, Pierluigi ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autism; Bufotenine; High performance liquid chromatography mass spectrometry; Schizophrenia

Indexed keywords

BUFOTENINE;

ADULT; ARTICLE; AUTISM; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERACTIVITY; LABORATORY TEST; MALE; MASS SPECTROMETRY; PROTEIN URINE LEVEL; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; URINALYSIS; URINARY EXCRETION; URINE BUFOTENINE LEVEL; URINE LEVEL;

EID: 77749314584     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. American Psychiatric Association DSM-IV-TR. (2005). Diagnostic and statistic manual of mental disorders, IVth edition, Italian Translation, Masson, Milan, 2005.
2. Ciprian-Ollivier J, Cetkovich-Bakmas MG, Boullosa O, Lopez-Mato A. (1988). Psicosis Esquizofrenicas. Teoria de la Transmetilacin Patologica. In: Ciprian-Ollivier, J. (Ed.), Psiquiatria Biologica. Fundamentos y Aplicacion Clinica. Cientifica Interamericana, Buenos Aires, pp. 75-87.
3. Cottrell AC, Mcleod MF, Mcleod WR. (1977). A bufotenine-like substance in the urine of schizophrenics. Am J Psychiatry. 134: 322-332.
4. First M, Spitzer R, Gibbon M, Williams JB. (1996). Structured Clinical Interview for DSM-IV AXIS I Disorders (Clinical Version) SCID-I Administration Booklet. Washington.DC: American Psychiatric Association.
5. Fischer E, Spatz H. (1968). Quantitative determination of an increased excretion of bufotenine in urine of schizophrenics. Arch. Psychiatr. Nervenkr. 211: 241-249.
6. Fischer E, Spatz H, Fledel T. (1971). Bufotenine like substances in form of glucuronide in schizophrenic and normal urines. Psychosomatics. 12: 278-280.
7. Forsström T, Tuominen J, Karkkäinen J. (2001). Determination of potentially hallucinogenic Ndimethylated indoleamines in human urine by HPLC/ESI-MS-MS. Scand. J. Clin. Lab. Invest. 61: 547-556.
8. Himwich HE, Jenkins RL, Fujimori M, Narasimhachari N, Ebersole M. (1972). A biochemical study of early infantile autism. J. Autism. Dev. Disord. 2: 114-126.
9. Kärkkäinen J, Räisänen M, Huttunen MO, Kallio E, Naukkarinen H, Virkkunen M. (1995). Urinary excretion of bufotenine (N,N-dimethyl-5-hydroxytryptamine) is increased in suspicious violent offenders: a confirmatory study. Psychiatry Res. 58: 145-152.
10. Kärkkäinen J, Forsstrom T, Tornaeus J, Wahala K, Kiuru P, Honkanen A, Stenman H, Turpeinin U, Hesso A. (2005). Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues. Scand. J. Clin. Lab. Invest. 65: 189-199.
11. Luchins D, Ban TA, Lehmann HE. (1978). A review of nicotinic acid, N-methylated indoleamines and schizophrenia. Int. Pharmacopsychiatry. 13: 16-33.
12. McBride MC. (2000). Bufotenine: toward an understanding of possible psychoactive mechanisms. J. Psychoactive Drugs. 32: 321-331.
13. Narasimhachari N, Himwich HE. (1972). The determination of bufotenine in urine of schizophrenic patients and normal controls, J. Psychiatr. Res. 9: 113-121.
14. Narasimhachari N, Himwich HE. (1975). Biochemical studies in early infantile autism. Biol. Psychiatry 10: 425-32.
15. Osmond H, Smythies J. (1952). Schizophrenia: a new approach. J. Ment. Sci. 98: 309-315.
16. Perry TL, Hansen S, MacDougall L. (1966). Urinary amines in chronic schizophrenia. Nature 212: 146-148.
17. Piggott LR. (1979). Overview of selected basic research in autism. J. Autism. Dev. Disord. 9: 199-218.
18. Räisänen MJ, Virkkunen M, Huttunen MO, Furman B, Kärkkäinen J. (1984). Increased urinary excretion of bufotenine by violent offenders with paranoid symptoms and family violence. Lancet. 8404: 700-701.
19. Rodnight R. (1956). Separation and characterization of urinary indoles resembling 5hydroxytryptamine and tryptamine. Biochem. J. 64: 621-626.
20. Saavedra JM, Axelrod J. (1972). Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science. 172: 1365-1366.
21. Schopler E, Reichler RJ, Renner BR. (1988). The Childhood Autism Rating Scale, Los Angeles: Western Psychological Services.
22. Siegel MA. (1956). Sensitive method for the detection of N,N-dimethylserotonin (bufotenine) in urine; failure to demonstrate its presence in the urine of schizophrenic and normal subjects. J. Psychiatr. Res. 3: 205-211.
23. Smythies JR. (1983). The transmethylation and one-carbon cycle hypothesis of schizophrenia, Psychol. Med. 13: 711-714.
24. Sparrow S, Balla D, Cicchetti D. (1984).Vineland Adaptive Behavior Scales, Circle pines, MN: American guidance Service; 1984.
25. Takeda N. (1994). Serotonin-degradative pathways in the toad (Bufo bufo japonicus) brain: clues to the pharmacological analysis of human psychiatric disorders. Comp. Biochem. Physiol. Pharmacol. Toxicol. Endocrinol. 107: 275-281.
26. Takeda N, Ikeda R, Ohba K, Kondo M. (1995). Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders, Neuroreport. 6: 2378-2380.
27. Tanimukai H, Ginther R, Spaide J, Himwich HE. (1967). Psychotomimetic indole compound in the urine of schizophrenics and mentally defective patients. Nature 216: 490-491.
28. Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA. (2000). Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 97: 129-135.
29. Wyatt RJ, Mandel LR, Ahn HS, Walker RW, Vanden Heuvel WJ. (1973). Gas chromatographic-mass-spectrometric isotope dilution determination of N,Ndimethyltryptamineconcentration in normals and psychiatric patients. Psychopharmacologia. 31: 265-270.